Kimialys

Kimialys is a privately-held, early-stage biotech tools company based in Lyon, France, focused on enabling advanced biosensing applications through its proprietary K-One surface chemistry platform. The company operates a hybrid business model, supplying custom K-One sensor chips and bioconjugates while also offering fee-for-service projects in antibody selection, SPR analysis, and LFA development. Following a successful €3.6 million Series A financing round, Kimialys is positioned to scale its technology and services, targeting the growing markets in proteomics, biotherapeutic characterization, and next-generation diagnostics.

K-One, a proprietary self-assembled monolayer (SAM) surface chemistry optimized for functionalizing gold nanoparticles, sensor chips, and electrodes to enhance biosensing applications.

Kimialys competes with established biosensor surface chemistry providers (e.g., Cytiva with carboxymethyl dextran chips) and numerous specialty CROs offering antibody discovery and characterization services. Its differentiation lies in the claimed superior performance of its proprietary K-One SAM in terms of robustness and reproducibility, particularly for complex samples. Success depends on proving this advantage translates to tangible time and cost savings for customers.